FGFR2 Amplification in Colorectal Adenocarcinoma...

Recent News

FGFR2 Amplification in Colorectal Adenocarcinoma

Cold Spring Harbor Laboratory Press; August 29, 2017 doi:10.1101/mcs.a001495

Jamal H Carter MD, Catherine E Cottrell PhD, Samantha N McNulty PhD, Katinka A Vigh-Conrad PhD, Stephen Lamp, Jonathan W Heusel MD, Eric J Duncavage MD


FGFR2 is recurrently amplified in 5% of gastric cancers and 1-4% of breast cancers; however, this molecular alteration has never been reported in a primary colorectal cancer specimen. Preclinical studies indicate that several FGFR tyrosine-kinase inhibitors (TKI), such as AZD4547, have in vitro activity against the FGFR2-amplified colorectal cell line, NCI-H716. The efficacy of these inhibitors is currently under investigation in clinical trials for breast and gastric cancer. Thus, better characterizing colorectal tumors for FGFR2 amplification could identify a subset of patients who may benefit from FGFR TKI therapies. Here, we describe a novel FGFR2 amplification identified by clinical next-generation sequencing (NGS) in a primary colorectal cancer. Further characterization of the tumor by immunohistochemistry showed neuroendocrine differentiation, similar to the reported properties of the NCI-H716 cell line. These findings demonstrate that the spectrum of potentially clinically actionable mutations detected by targeted clinical sequencing panels is not just limited to single nucleotide polymorphisms and insertions/deletions, but also copy number alterations.

Empire Genomic's Control 10 and Custom FISH probes were used in this publication.

To Access Article, Click Here

Have Any Questions Regarding This Article? Contact Our Team Today